Sequencio Therapeutics Company Limited, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., announced that the Society for Immunotherapy of Cancer (SITC) has selected two abstracts for presentation at its 41st Annual Meeting, to be held 4-8 November 2026 in Phoenix, Arizona. The data, shared via Media OutReach Newswire, offers early evidence that the company's lead cancer vaccine programmes may be able to overcome two central obstacles in immuno-oncology: helping the immune system recognize cancer cells and countering tumour evasion mechanisms.
The two studies evaluate components of Sequencio's Prime–Infiltrate–Ignite–Translate (PINT) translational research framework. Both vaccines generated targeted immune responses against their intended cancer-related targets, supporting the Prime element. The TROP2 vaccine combination increased activated T cells within tumours, while the PD-L1/PRAME vaccine increased tumour-infiltrating immune cells and other indicators of local immune activity, supporting Infiltrate. The use of checkpoint targeting and evidence of a more immune-active tumour environment support Ignite. Both studies demonstrated meaningful tumour growth inhibition, and the PD-L1/PRAME vaccine also generated a durable antigen-specific immune response, as shown by protection against tumour rechallenge. The use of humanised preclinical models contributes to Translate by helping researchers assess how findings may be relevant to humans.
The first abstract (Number 583) covers CKLS118, an hTROP2-targeted circRNA-LNP therapeutic cancer vaccine, evaluated in combination with anti-PD-1 therapy in two TROP2-positive tumour models. The vaccine enhanced the anti-tumour activity of lower-dose anti-PD-1 treatment and significantly increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumours. In the 4T1-hTROP2 model, tumour growth inhibition reached 74.7% and 88.9% when combined with 0.3 and 1.0 mg/kg anti-PD-1, respectively, compared with 28.9% and 68.6% with anti-PD-1 alone. These findings support further development of CKLS118 with checkpoint inhibition and a potential dose-sparing strategy.
The second abstract (Number 1045) details CKLS202, a human PD-L1/PRAME dual-antigen vaccine designed to combine tumour-antigen targeting with PD-L1-directed immune modulation. In humanised models, vaccination induced robust PRAME-specific T-cell responses, anti-human PD-L1 antibody titres above 1:16,000 and functional hPD-1/hPD-L1 blockade. In the efficacy model, vaccination achieved 65% tumour growth inhibition and was associated with increased tumour-infiltrating CD4+ cells (0.94% to 2.97%), more than twofold increases in interferon-γ and granzyme B, and a more than fivefold reduction in the M2 macrophage marker CD163, consistent with a shift toward a more immune-active tumour environment. Vaccinated tumour-free mice were also protected against tumour rechallenge, supporting durable antigen-specific immunity.
Dr Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, said the posters provide an important opportunity to share new data with the international immuno-oncology community. He noted that while the two programmes take distinct approaches, both are designed to engage multiple elements of the PINT framework. The findings may also help inform future clinical development in peri-operative settings, where lower tumour burden may give vaccine-induced immunity a greater opportunity to control residual disease. The presentation of these data at a major oncology meeting underscores the progress of Sequencio's vaccine candidates and their potential to advance toward human clinical trials.
